Risk factors

Roivant Sciences (ROIV) risk factors

Item 1A of every Roivant Sciences Ltd. 10-K on file, and what changed from one year to the next.

Open ROIV in Gloomberb →
  • FY2026 10-K risk factors

    98 risks, 18 new, 22 dropped, 33 reworded since the prior year. Foreign-CMO restrictions, including the BIOSECURE Act, could disrupt manufacturing, supply chains and clinical programs.

    Filed May 20, 2026
  • FY2025 10-K risk factors

    102 risks. Roivant Sciences is a clinical-stage biopharmaceutical company with a unique Vant business structure and limited operating history. Key risks involve clinical trial uncertainty, reliance on product acquisitions and licensing, regulatory compliance, and extensive capital allocation. The company holds significant cash and marketable securities subject to macroeconomic conditions.

    Filed May 29, 2025